BioTuesdays

Tag - PNT

Point Biopharma

Brookline starts POINT Biopharma at buy; PT $23

Brookline Capital Markets initiated coverage of POINT Biopharma (NASDAQ:PNT) with a “buy” rating and $23 price target. The stock closed at $8.07 on Nov. 30. POINT is a late-stage clinical oncology company focused on...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.